Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Kyung-Soo Kim  (Kim KS) 14 Articles
Guideline/Fact Sheet
Fatty Liver & Diabetes Statistics in Korea: Nationwide Data 2009 to 2017
Eugene Han, Kyung-Do Han, Yong-ho Lee, Kyung-Soo Kim, Sangmo Hong, Jung Hwan Park, Cheol-Young Park, on Behalf of Fatty Liver Research Group of the Korean Diabetes Association
Diabetes Metab J. 2023;47(3):347-355.   Published online March 29, 2023
DOI: https://doi.org/10.4093/dmj.2022.0444
  • 3,491 View
  • 204 Download
  • 5 Web of Science
  • 9 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This study investigated the changes of fatty liver disease prevalence in general Korean population.
Methods
This study analyzed data from the Korean National Health Insurance Service from 2009 to 2017 that included individuals aged 20 years or older who had undergone a medical health examination. Fatty liver disease was assessed using the fatty liver index (FLI). The disease severity was defined by FLI cutoff, ≥30 as moderate, and ≥60 as severe fatty liver disease.
Results
The prevalence of Korean adults aged 20 years or over with fatty liver disease (FLI ≥60) increased from 13.3% in 2009 to 15.5% in 2017 (P for trend <0.001). The increase in fatty liver disease prevalence was prominent in men (from 20.5% to 24.2%) and the young age (20 to 39 years) group (from 12.8% to 16.4%) (P for interaction <0.001). The prevalence of fatty liver disease was the highest in type 2 diabetes mellitus (T2DM, 29.6%) population compared to that of prediabetes or normoglycemia (10.0% and 21.8%) in 2017. The prevalence of fatty liver disease had statistically increased in individuals with T2DM and prediabetes (P for trend <0.001). Its prevalence increased more steeply in the young-aged population with T2DM, from 42.2% in 2009 to 60.1% in 2017. When applying a lower FLI cutoff (≥30) similar results were observed.
Conclusion
The prevalence of fatty liver disease in the Korean population has increased. Individuals who are young, male, and have T2DM are vulnerable to fatty liver disease.

Citations

Citations to this article as recorded by  
  • Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea
    Min Gu Kang, Chang Hun Lee, Chen Shen, Jong Seung Kim, Ji Hyun Park
    Journal of Hepatology.2024; 80(5): e216.     CrossRef
  • Repeated detection of non‐alcoholic fatty liver disease increases the incidence risk of type 2 diabetes in young adults
    Jin Hwa Kim, Young Sang Lyu, Mee Kyoung Kim, Sang Yong Kim, Ki‐Hyun Baek, Ki‐Ho Song, Kyungdo Han, Hyuk‐Sang Kwon
    Diabetes, Obesity and Metabolism.2024; 26(1): 180.     CrossRef
  • Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
    Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim
    Metabolism.2024; 152: 155789.     CrossRef
  • Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
    Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    BMJ.2024; : e076388.     CrossRef
  • Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
    Scott L. Friedman
    Diabetes & Metabolism Journal.2024; 48(2): 161.     CrossRef
  • Reply to G. Wang et al
    Joo-Hyun Park, Jung Yong Hong, Kyungdo Han
    Journal of Clinical Oncology.2023; 41(32): 5070.     CrossRef
  • The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review
    Teodora Biciusca, Sorina Ionelia Stan, Mara Amalia Balteanu, Ramona Cioboata, Alice Elena Ghenea, Suzana Danoiu, Ana-Maria Bumbea, Viorel Biciusca
    Diagnostics.2023; 13(21): 3316.     CrossRef
  • Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?
    Eugene Han, Yong-ho Lee
    Clinical and Molecular Hepatology.2023; 29(4): 980.     CrossRef
  • Approach to Fatty Liver Disease in Patients with Type 2 Diabetes
    Ji Cheol Bae
    The Journal of Korean Diabetes.2023; 24(3): 107.     CrossRef
Metabolic Risk/Epidemiology
Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
Diabetes Metab J. 2023;47(2):220-231.   Published online January 12, 2023
DOI: https://doi.org/10.4093/dmj.2021.0327
  • 65,535 View
  • 282 Download
  • 9 Web of Science
  • 10 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We investigated whether metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with an elevated risk of all-cause and cardiovascular mortality using a large-scale health examination cohort.
Methods
A total of 394,835 subjects in the Kangbuk Samsung Health Study cohort were enrolled from 2002 to 2012. Participants were categorized by the presence of nonalcoholic fatty liver disease (NAFLD) and MAFLD as follows: normal subjects; patients with both NAFLD and MAFLD; patients with NAFLD only; and patients with MAFLD only. Cox proportional hazards models were used to analyze the risk of mortality.
Results
During a median 5.7 years of follow-up, 20.69% was patients with both NAFLD and MAFLD, 1.51% was patients with NAFLD only, and 4.29% was patients with MAFLD only. All-cause and cardiovascular death was higher in patients with MAFLD than those without MAFLD (P<0.001, respectively). In patients with MAFLD only, the hazard ratio (HR) of all-cause and cardiovascular death was 1.35 (95% confidence interval [CI], 1.13 to 1.60) and 1.90 (95% CI, 1.26 to 2.88) after adjusting for age, which lost its statistical significance by multivariable adjustments. Compared to patients with less than two components of metabolic dysfunction, patients with more than two components of metabolic dysfunction were a higher risk of cardiovascular death (HR, 2.05; 95% CI, 1.25 to 3.38) and only women with more than two components of metabolic dysfunction were a higher risk of all-cause death (HR, 1.44; 95% CI, 1.02 to 2.03).
Conclusion
MAFLD criteria could identify a high-risk group for all-cause and cardiovascular death.

Citations

Citations to this article as recorded by  
  • Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
    Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim
    Metabolism.2024; 152: 155789.     CrossRef
  • Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
    Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    BMJ.2024; : e076388.     CrossRef
  • Sex differences in mortality and liver‐related events in non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
    Huimin Zhou, Haiyan Chen, Hanxiao Lu, Bo Wu, Shuo Zhang, Yuanlong Gu, Guangwen Zhou, Jie Xiang, Jun Yang
    Liver International.2024;[Epub]     CrossRef
  • Association between dietary carbohydrate to fiber ratio and metabolic dysfunction associated fatty liver disease in adults: evidence from the NHANES 2017–2020
    Zhenmin Liu, Taiyong Fang
    Journal of Health, Population and Nutrition.2024;[Epub]     CrossRef
  • Comparison of Outcomes Between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-alcoholic Fatty Liver Disease: A Meta-Analysis
    Ghazala S Virk, Jaahnavi Vajje, Nausheen K Virk, Raam Mannam, Wajeeh Rehman, Naglaa G Ghobriel , Irfan-ud-din Mian, Muhammad Usama
    Cureus.2023;[Epub]     CrossRef
  • Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study
    Zhi-Qin Xie, Hong-Xia Li, Bing-Kun Wang, Zhao-Ming Yang, Zi-Yu Zhang, Wen-Liang Tan, Wen-Xin Li, Qing-Bin Wang, Lei Yang, Hong-Kai Zhuang, Chen-Wei Tang, Chang-Zhen Shang, Ya-Jin Chen
    European Journal of Internal Medicine.2023; 110: 62.     CrossRef
  • Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
    Han Na Jung, Chang Hee Jung
    Diabetes & Metabolism Journal.2023; 47(2): 198.     CrossRef
  • Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
    Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
    Metabolism.2023; 145: 155612.     CrossRef
  • Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes
    Karl Vaz, Daniel Clayton-Chubb, Ammar Majeed, John Lubel, David Simmons, William Kemp, Stuart K. Roberts
    Hepatology International.2023; 17(5): 1082.     CrossRef
  • Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Soyeon Shin, Jaeyoung Kim, Ju Yeon Lee, Jun Kim, Chang-Myung Oh
    Journal of Obesity & Metabolic Syndrome.2023; 32(4): 289.     CrossRef
Metabolic Risk/Epidemiology
Postprandial Free Fatty Acids at Mid-Pregnancy Increase the Risk of Large-for-Gestational-Age Newborns in Women with Gestational Diabetes Mellitus
So-Yeon Kim, Young Shin Song, Soo-Kyung Kim, Yong-Wook Cho, Kyung-Soo Kim
Diabetes Metab J. 2022;46(1):140-148.   Published online August 9, 2021
DOI: https://doi.org/10.4093/dmj.2021.0023
  • 4,949 View
  • 160 Download
  • 3 Web of Science
  • 3 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
To investigate the association between free fatty acid (FFA) level at mid-pregnancy and large-for-gestational-age (LGA) newborns in women with gestational diabetes mellitus (GDM).
Methods
We enrolled 710 pregnant women diagnosed with GDM from February 2009 to October 2016. GDM was diagnosed by a ‘two-step’ approach with Carpenter and Coustan criteria. We measured plasma lipid profiles including fasting and 2-hour postprandial FFA (2h-FFA) levels at mid-pregnancy. LGA was defined if birthweights of newborns were above the 90th percentile for their gestational age.
Results
Mean age of pregnant women in this study was 33.1 years. Mean pre-pregnancy body mass index (BMI) was 22.4 kg/m2. The prevalence of LGA was 8.3% (n=59). Levels of 2h-FFA were higher in women who delivered LGA newborns than in those who delivered non-LGA newborns (416.7 μEq/L vs. 352.5 μEq/L, P=0.006). However, fasting FFA was not significantly different between the two groups. The prevalence of delivering LGA newborns was increased with increasing tertile of 2h-FFA (T1, 4.3%; T2, 9.8%; T3, 10.7%; P for trend <0.05). After adjustment for maternal age, pre-pregnancy BMI, and fasting plasma glucose, the highest tertile of 2h-FFA was 2.38 times (95% confidence interval, 1.11 to 5.13) more likely to have LGA newborns than the lowest tertile. However, there was no significant difference between groups according to fasting FFA tertiles.
Conclusion
In women with GDM, a high 2h-FFA level (but not fasting FFA) at mid-pregnancy is associated with an increasing risk of delivering LGA newborns.

Citations

Citations to this article as recorded by  
  • Advances in free fatty acid profiles in gestational diabetes mellitus
    Haoyi Du, Danyang Li, Laura Monjowa Molive, Na Wu
    Journal of Translational Medicine.2024;[Epub]     CrossRef
  • Modulation of gut microbiota and lipid metabolism in rats fed high-fat diets by Ganoderma lucidum triterpenoids
    Aijun Tong, Weihao Wu, Zhengxin Chen, Jiahui Wen, Ruibo Jia, Bin Liu, Hui Cao, Chao Zhao
    Current Research in Food Science.2023; 6: 100427.     CrossRef
  • Fetal Abdominal Obesity Detected at 24 to 28 Weeks of Gestation Persists until Delivery Despite Management of Gestational Diabetes Mellitus (Diabetes Metab J 2021;45:547-57)
    Wonjin Kim, Soo Kyung Park, Yoo Lee Kim
    Diabetes & Metabolism Journal.2021; 45(6): 970.     CrossRef
Basic Research
Role of Autophagy in Granulocyte-Colony Stimulating Factor Induced Anti-Apoptotic Effects in Diabetic Cardiomyopathy
Guang-Yin Shen, Jeong-Hun Shin, Yi-Sun Song, Hyun-Woo Joo, In-Hwa Park, Jin-Hee Seong, Na-Kyoung Shin, A-Hyeon Lee, Young Jong Cho, Yonggu Lee, Young-Hyo Lim, Hyuck Kim, Kyung-Soo Kim
Diabetes Metab J. 2021;45(4):594-605.   Published online February 26, 2021
DOI: https://doi.org/10.4093/dmj.2020.0049
  • 7,176 View
  • 147 Download
  • 3 Web of Science
  • 2 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We previously, reported that granulocyte-colony stimulating factor (G-CSF) reduces cardiomyocyte apoptosis in diabetic cardiomyopathy. However, the underlying mechanisms are not yet fully understood. Therefore, we investigated whether the mechanisms underlying of the anti-apoptotic effects of G-CSF were associated with autophagy using a rat model of diabetic cardiomyopathy.
Methods
Diabetic cardiomyopathy was induced in rats through a high-fat diet combined with low-dose streptozotocin and the rats were then treated with G-CSF for 5 days. Rat H9c2 cardiac cells were cultured under high glucose conditions as an in vitro model of diabetic cardiomyopathy. The extent of apoptosis and protein levels related to autophagy (Beclin-1, microtubule-binding protein light chain 3 [LC3]-II/LC3-I ratio, and P62) were determined for both models. Autophagy determination was performed using an Autophagy Detection kit.
Results
G-CSF significantly reduced cardiomyocyte apoptosis in the diabetic myocardium in vivo and led to an increase in Beclin-1 level and the LC3-II/LC3-I ratio, and decreased P62 level. Similarly, G-CSF suppressed apoptosis, increased Beclin-1 level and LC3-II/LC3-I ratio, and decreased P62 level in high glucose-induced H9c2 cardiac cells in vitro. These effects of G-CSF were abrogated by 3-methyladenine, an autophagy inhibitor. In addition, G-CSF significantly increased autophagic flux in vitro.
Conclusion
Our results suggest that the anti-apoptotic effect of G-CSF might be significantly associated with the up-regulation of autophagy in diabetic cardiomyopathy.

Citations

Citations to this article as recorded by  
  • Ginkgo biloba extract protects against diabetic cardiomyopathy by restoring autophagy via adenosine monophosphate‐activated protein kinase/mammalian target of the rapamycin pathway modulation
    Xueyao Yang, Xin Zhao, Yanfei Liu, Yue Liu, Libo Liu, Ziyu An, Haoran Xing, Jinfan Tian, Xiantao Song
    Phytotherapy Research.2023; 37(4): 1377.     CrossRef
  • Perspectives for Forkhead box transcription factors in diabetic cardiomyopathy: Their therapeutic potential and possible effects of salvianolic acids
    Ronghui Han, Hemeng Huang, Weiyi Xia, Jingjin Liu, Hui Luo, Jing Tang, Zhengyuan Xia
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
Basic Research
Umbilical Cord-Mesenchymal Stem Cell-Conditioned Medium Improves Insulin Resistance in C2C12 Cell
Kyung-Soo Kim, Yeon Kyung Choi, Mi Jin Kim, Jung Wook Hwang, Kyunghoon Min, Sang Youn Jung, Soo-Kyung Kim, Yong-Soo Choi, Yong-Wook Cho
Diabetes Metab J. 2021;45(2):260-269.   Published online July 10, 2020
DOI: https://doi.org/10.4093/dmj.2019.0191
  • 9,429 View
  • 205 Download
  • 8 Web of Science
  • 8 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

Umbilical cord-mesenchymal stem cell-conditioned medium (UC-MSC-CM) has emerged as a promising cell-free therapy. The aim of this study was to explore the therapeutic effects of UC-MSC-CM on insulin resistance in C2C12 cell.

Methods

Insulin resistance was induced by palmitate. Effects of UC-MSC-CM on insulin resistance were evaluated using glucose uptake, glucose transporter type 4 (GLUT4) translocation, the insulin-signaling pathway, and mitochondrial contents and functions in C2C12 cell.

Results

Glucose uptake was improved by UC-MSC-CM. UC-MSC-CM treatment increased only in membranous GLUT4 expression, not in cytosolic GLUT4 expression. It restored the insulin-signaling pathway in insulin receptor substrate 1 and protein kinase B. Mitochondrial contents evaluated by mitochondrial transcription factor A, mitochondrial DNA copy number, and peroxisome proliferator-activated receptor gamma coactivator 1-alpha were increased by UC-MSC-CM. In addition, UC-MSC-CM significantly decreased mitochondrial reactive oxygen species and increased fatty acid oxidation and mitochondrial membrane potential. There was no improvement in adenosine triphosphate (ATP) contents, but ATP synthesis was improved by UC-MSC-CM. Cytokine and active factor analysis of UC-MSC-CM showed that it contained many regulators inhibiting insulin resistance.

Conclusion

UC-MSC-CM improves insulin resistance with multiple mechanisms in C2C12 cell.

Citations

Citations to this article as recorded by  
  • Neurotransmitters in Type 2 Diabetes and the Control of Systemic and Central Energy Balance
    Amnah Al-Sayyar, Maha M. Hammad, Michayla R. Williams, Mohammed Al-Onaizi, Jehad Abubaker, Fawaz Alzaid
    Metabolites.2023; 13(3): 384.     CrossRef
  • Neuroprotective Effect of Wharton’s Jelly-Derived Mesenchymal Stem Cell-Conditioned Medium (WJMSC-CM) on Diabetes-Associated Cognitive Impairment by Improving Oxidative Stress, Neuroinflammation, and Apoptosis
    Zohre Aghaei, Narges Karbalaei, Mohammad Reza Namavar, Masoud Haghani, Mahboobeh Razmkhah, Mahdi Khorsand Ghaffari, Marzieh Nemati, Andrea Ballini
    Stem Cells International.2023; 2023: 1.     CrossRef
  • Mesenchymal-Stem Cell-Derived Conditioned Media Versus Exosomes in the Treatment of Rat Model of Polycystic Ovary: An Attempt to Understand the Underlying Mechanisms (Biochemical and Histological Study)
    Soha Abd-elkawy Abd-elwahab, Noura Hassan Khamis, Rehab Ahmed Rifaai, Nashwa Fathy Gamal El-Tahawy, Randa Ahmed Ibrahim
    Microscopy and Microanalysis.2023; 29(3): 1244.     CrossRef
  • Therapeutic Potential of Mesenchymal Stem Cell‐Derived Conditioned Medium for Diabetes Mellitus and Related Complications
    Basak Isildar, Serbay Ozkan, Meral Koyuturk
    Advanced Therapeutics.2023;[Epub]     CrossRef
  • Treatment of type 2 diabetes mellitus with stem cells and antidiabetic drugs: a dualistic and future-focused approach
    Priyamvada Amol Arte, Kanchanlata Tungare, Mustansir Bhori, Renitta Jobby, Jyotirmoi Aich
    Human Cell.2023; 37(1): 54.     CrossRef
  • Perinatal Stem Cell Therapy to Treat Type 1 Diabetes Mellitus: A Never-Say-Die Story of Differentiation and Immunomodulation
    Francesca Paris, Valeria Pizzuti, Pasquale Marrazzo, Andrea Pession, Francesco Alviano, Laura Bonsi
    International Journal of Molecular Sciences.2022; 23(23): 14597.     CrossRef
  • Mesenchymal Stem Cell-Derived Apoptotic Bodies: Biological Functions and Therapeutic Potential
    Huixue Tang, Huikun Luo, Zihan Zhang, Di Yang
    Cells.2022; 11(23): 3879.     CrossRef
  • Human umbilical cord mesenchymal stem cells in type 2 diabetes mellitus: the emerging therapeutic approach
    Andreia Gomes, Pedro Coelho, Raquel Soares, Raquel Costa
    Cell and Tissue Research.2021; 385(3): 497.     CrossRef
Letter: The Risk of Diabetes on Clinical Outcomes in Patients with Coronavirus Disease 2019: A Retrospective Cohort Study (Diabetes Metab J 2020;44:405–13)
So-Yeon Kim, Kyung-Soo Kim
Diabetes Metab J. 2020;44(4):621-622.   Published online August 21, 2020
DOI: https://doi.org/10.4093/dmj.2020.0151
  • 4,890 View
  • 55 Download
  • 1 Web of Science
  • 1 Crossref
PDFPubReader   ePub   

Citations

Citations to this article as recorded by  
  • Evolution of a Cohort of COVID-19 Infection Suspects Followed-Up from Primary Health Care
    Valle Coronado-Vázquez, Maria del Valle Ramírez-Durán, Juan Gómez-Salgado, María Silvia Dorado-Rabaneda, Elena Benito-Alonso, Marina Holgado-Juan, Cristina Bronchalo-González
    Journal of Personalized Medicine.2021; 11(6): 459.     CrossRef
Technology/Device
Role of MicroRNA-34a in Anti-Apoptotic Effects of Granulocyte-Colony Stimulating Factor in Diabetic Cardiomyopathy
In-Hwa Park, Yi-Sun Song, Hyun-Woo Joo, Guang-Yin Shen, Jin-Hee Seong, Na-Kyoung Shin, Young Jong Cho, Yonggu Lee, Jeong Hun Shin, Young-Hyo Lim, Hyuck Kim, Kyung-Soo Kim
Diabetes Metab J. 2020;44(1):173-185.   Published online April 23, 2019
DOI: https://doi.org/10.4093/dmj.2018.0211
  • 5,470 View
  • 74 Download
  • 11 Web of Science
  • 10 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

Recent studies have shown that microRNAs (miRNAs) are involved in the process of cardiomyocyte apoptosis. We have previously reported that granulocyte-colony stimulating factor (G-CSF) ameliorated diastolic dysfunction and attenuated cardiomyocyte apoptosis in a rat model of diabetic cardiomyopathy. In this study, we hypothesized a regulatory role of cardiac miRNAs in the mechanism of the anti-apoptotic effect of G-CSF in a diabetic cardiomyopathy rat model.

Methods

Rats were given a high-fat diet and low-dose streptozotocin injection and then randomly allocated to receive treatment with either G-CSF or saline. H9c2 rat cardiomyocytes were cultured under a high glucose (HG) condition to induce diabetic cardiomyopathy in vitro. We examined the extent of apoptosis, miRNA expression, and miRNA target genes in the myocardium and H9c2 cells.

Results

G-CSF treatment significantly decreased apoptosis and reduced miR-34a expression in diabetic myocardium and H9c2 cells under the HG condition. G-CSF treatment also significantly increased B-cell lymphoma 2 (Bcl-2) protein expression as a target for miR-34a. In addition, transfection with an miR-34a mimic significantly increased apoptosis and decreased Bcl-2 luciferase activity in H9c2 cells.

Conclusion

Our results indicate that G-CSF might have an anti-apoptotic effect through down-regulation of miR-34a in a diabetic cardiomyopathy rat model.

Citations

Citations to this article as recorded by  
  • The study of the mechanism of non-coding RNA regulation of programmed cell death in diabetic cardiomyopathy
    Bingrui Zhang, Hua Wu, Jingwen Zhang, Cong Cong, Lin Zhang
    Molecular and Cellular Biochemistry.2024;[Epub]     CrossRef
  • Non-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction
    Elisabeth A. Jalink, Amber W. Schonk, Reinier A. Boon, Rio P. Juni
    Frontiers in Cardiovascular Medicine.2024;[Epub]     CrossRef
  • Dynamic interplay of microRNA in diseases and therapeutic
    Neha Kargutkar, Priya Hariharan, Anita Nadkarni
    Clinical Genetics.2023; 103(3): 268.     CrossRef
  • LGR5+ Intestinal Stem Cells Display Sex-Dependent Radiosensitivity
    Ryan C. Zitter, Rishi Man Chugh, Payel Bhanja, Bruce F. Kimler, Subhrajit Saha
    Cells.2023; 13(1): 46.     CrossRef
  • Female Mice are More Resistant to the Mixed-Field (67% Neutron + 33% Gamma) Radiation-Induced Injury in Bone Marrow and Small Intestine than Male Mice due to Sustained Increases in G-CSF and the Bcl-2/Bax Ratio and Lower miR-34a and MAPK Activation
    Juliann G. Kiang, Georgetta Cannon, Matthew G. Olson, Joan T. Smith, Marsha N. Anderson, Min Zhai, M. Victoria Umali, Kevin Ho, Connie Ho, Wanchang Cui, Mang Xiao
    Radiation Research.2022;[Epub]     CrossRef
  • Potential Role of Natural Plant Medicine Cyclocarya paliurus in the Treatment of Type 2 Diabetes Mellitus
    Han Wang, Cheng Tang, Zezheng Gao, Yishan Huang, Boxun Zhang, Jiahua Wei, Linhua Zhao, Xiaolin Tong, Yong Xu
    Journal of Diabetes Research.2021; 2021: 1.     CrossRef
  • Ghrelin, a novel therapy, corrects cytokine and NF-κB-AKT-MAPK network and mitigates intestinal injury induced by combined radiation and skin-wound trauma
    Juliann G. Kiang, Joan T. Smith, Georgetta Cannon, Marsha N. Anderson, Connie Ho, Min Zhai, Wanchang Cui, Mang Xiao
    Cell & Bioscience.2020;[Epub]     CrossRef
  • Evaluation of biomarkers in liver following Solanum melongena green calyx administration in diabetic rats
    Shiva Roshankhah, Ahmad Shabanizadeh, Amir Abdolmaleki, Mohammad Reza Gholami, Mohammad Reza Salahshoor
    Journal of Diabetes & Metabolic Disorders.2020; 19(2): 1115.     CrossRef
  • Diabetic cardiomyopathy: definition, diagnosis criteria, treatment directions and prevention of heart failure
    N. A. Koziolova, P. G. Karavaev, A. S. Veklich
    South Russian Journal of Therapeutic Practice.2020; 1(2): 93.     CrossRef
  • The Potential Role of MicroRNA in Diabetic Cardiomyopathy
    Jin Hwa Kim
    Diabetes & Metabolism Journal.2020; 44(1): 54.     CrossRef
Clinical Diabetes & Therapeutics
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Kyung-Soo Kim, Byung-Wan Lee, Yong Jin Kim, Dae Ho Lee, Bong-Soo Cha, Cheol-Young Park
Diabetes Metab J. 2019;43(2):127-143.   Published online April 15, 2019
DOI: https://doi.org/10.4093/dmj.2019.0034
  • 7,621 View
  • 138 Download
  • 25 Web of Science
  • 35 Crossref
AbstractAbstract PDFPubReader   

Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. Among many proposed treatments, weight reduction is the only approved option for NAFLD to date. However, it is not easy to maintain weight loss by lifestyle modification alone; pharmacological treatments are helpful in this regard. Although many drugs have been investigated, pioglitazone could be a first-line therapy in patients with NAFLD and diabetes. Many more drugs are currently being developed and investigated, and it is likely that combination strategies will be used for future treatment of NAFLD and diabetes. Attention should be paid to the management of NAFLD and diabetes and efforts should be made to intervene early and individualize treatment of NAFLD in patients with diabetes.

Citations

Citations to this article as recorded by  
  • Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
    Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    BMJ.2024; : e076388.     CrossRef
  • Research Progress of Traditional Chinese Medicine and Western Medicine on Non-Alcoholic Fatty Liver Disease
    强江 郭
    Advances in Clinical Medicine.2024; 14(03): 561.     CrossRef
  • Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: Bi-directional opportunities to multiply preventive strategies
    Alhussain Yasin, Madison Nguyen, Angad Sidhu, Priyanka Majety, Jared Spitz, Amon Asgharpour, Mohammad S. Siddiqui, Laurence S. Sperling, Arshed A. Quyyumi, Anurag Mehta
    Diabetes Research and Clinical Practice.2024; 211: 111650.     CrossRef
  • Effect of aerobic training with silymarin consumption on glycemic indices and liver enzymes in men with type 2 diabetes
    Keyvan Ghalandari, Mojtaba Shabani, Ali Khajehlandi, Amin Mohammadi
    Archives of Physiology and Biochemistry.2023; 129(1): 76.     CrossRef
  • Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes & Metabolism Journal.2023; 47(2): 220.     CrossRef
  • Comparative antihypertensive efficacy of combinations of azilsartan medoxomil or olmesartan medoxomil with amlodipine in patients with arterial hypertension, type 2 diabetes mellitus and non-alcoholic fatty liver disease
    I. А. Lukonin, V. V. Skibitsky, A. V. Fendrikova, A. V. Skibitsky, I. A. Antipov
    South Russian Journal of Therapeutic Practice.2023; 4(1): 68.     CrossRef
  • An Ethyl Acetate Extract of Eryngium carlinae Inflorescences Attenuates Oxidative Stress and Inflammation in the Liver of Streptozotocin-Induced Diabetic Rats
    Cristian M. Trejo-Hurtado, Cinthia I. Landa-Moreno, Jenaro Lemus-de la Cruz, Donovan J. Peña-Montes, Rocío Montoya-Pérez, Rafael Salgado-Garciglia, Salvador Manzo-Avalos, Christian Cortés-Rojo, Juan Luis Monribot-Villanueva, José Antonio Guerrero-Analco,
    Antioxidants.2023; 12(6): 1235.     CrossRef
  • Pharmacogenetics of glucagon-like peptide-1 agonists in the treatment of type 2 diabetes mellitus
    Iu.G. Samoilova, A.E. Stankova, M.V. Matveeva, O.E. Vaizova, D.V. Podchinenova, D.A. Kudlay, T.A. Filippova, I.R. Grishkevich
    Profilakticheskaya meditsina.2023; 26(12): 95.     CrossRef
  • Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
    Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee
    Hepatobiliary & Pancreatic Diseases International.2022; 21(3): 241.     CrossRef
  • Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease
    Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park
    Obesity.2022; 30(6): 1279.     CrossRef
  • Evaluating Triglyceride and Glucose Index as a Simple and Easy-to-Calculate Marker for All-Cause and Cardiovascular Mortality
    Kyung-Soo Kim, Sangmo Hong, You-Cheol Hwang, Hong-Yup Ahn, Cheol-Young Park
    Journal of General Internal Medicine.2022; 37(16): 4153.     CrossRef
  • Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents
    Kyung-Soo Kim
    The Journal of Korean Diabetes.2022; 23(2): 83.     CrossRef
  • Efficacy and mechanism of Jiedu Tongluo Tiaogan Formula in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease: Study protocol for a parallel-armed, randomized controlled trial
    Jinghan Xu, Chunli Piao, Yue Qu, Tianjiao Liu, Yuting Peng, Qi Li, Xiaohua Zhao, Pei Li, Xuemin Wu, Yawen Fan, Binqin Chen, Jie Yang
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Intestinal microbiota in the treatment of metabolically associated fatty liver disease
    Ji-Shuai Wang, Jin-Chun Liu
    World Journal of Clinical Cases.2022; 10(31): 11240.     CrossRef
  • Efficiency of combined antihypertensive pharmacotherapy in patients with arterial hypertension, combined with type 2 diabetes mellitus and non-alcoholic fatty liver disease
    I. A. Lukonin, V. V. Skibitsky, A. V. Fendrikova, I. I. Pavlyuchenko, K. Yu. Lazarev, F. A. Kovalenko
    Systemic Hypertension.2022; 19(1): 31.     CrossRef
  • Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats
    Yujie Zhong, Zhiman Li, Ruyi Jin, Yanpeng Yao, Silan He, Min Lei, Xin Wang, Chao Shi, Li Gao, Xiaoli Peng
    Nutrients.2022; 14(23): 4994.     CrossRef
  • Pluchea indica Leaf Extract Alleviates Dyslipidemia and Hepatic Steatosis by Modifying the Expression of Lipid Metabolism-Related Genes in Rats Fed a High Fat-High Fructose Diet
    Patcharin Singdam, Jarinyaporn Naowaboot, Laddawan Senggunprai, Kampeebhorn Boonloh, Patchareewan Pannangpetch
    Preventive Nutrition and Food Science.2022; 27(4): 384.     CrossRef
  • NAFLDin type 2 diabetes mellitus: Still many challenging questions
    Simona Cernea, Itamar Raz
    Diabetes/Metabolism Research and Reviews.2021;[Epub]     CrossRef
  • Umbilical Cord-Mesenchymal Stem Cell-Conditioned Medium Improves Insulin Resistance in C2C12 Cell
    Kyung-Soo Kim, Yeon Kyung Choi, Mi Jin Kim, Jung Wook Hwang, Kyunghoon Min, Sang Youn Jung, Soo-Kyung Kim, Yong-Soo Choi, Yong-Wook Cho
    Diabetes & Metabolism Journal.2021; 45(2): 260.     CrossRef
  • Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes Therapy.2021; 12(1): 171.     CrossRef
  • Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
    Sook Jung Lee, Byung-Wan Lee
    The Journal of Korean Diabetes.2021; 22(1): 38.     CrossRef
  • Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
    A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova, E. V. Bryukhovetskaya
    Russian Journal of Gastroenterology, Hepatology, Coloproctology.2021; 31(2): 14.     CrossRef
  • NAFLD and its link with diabetes: Why we should be worried
    Louise Cremonesini, Emma Harkin
    Independent Nurse.2021; 2021(8): 20.     CrossRef
  • Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
    Eugene Han, Mi Kyung Kim, Byoung Kuk Jang, Hye Soon Kim
    Diabetes & Metabolism Journal.2021; 45(5): 698.     CrossRef
  • Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study
    Jun Hyung Kim, Jin Sil Moon, Seok Joon Byun, Jun Hyeok Lee, Dae Ryong Kang, Ki Chul Sung, Jang Young Kim, Ji Hye Huh
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
    Rohit Loomba, Erin Morgan, Lynnetta Watts, Shuting Xia, Lisa A Hannan, Richard S Geary, Brenda F Baker, Sanjay Bhanot
    The Lancet Gastroenterology & Hepatology.2020; 5(9): 829.     CrossRef
  • Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
    Eugene Han, Yongin Cho, Kyung-won Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-wan Lee
    Medicine.2020; 99(33): e21038.     CrossRef
  • Metabolic liver disease in diabetes – From mechanisms to clinical trials
    Bedair Dewidar, Sabine Kahl, Kalliopi Pafili, Michael Roden
    Metabolism.2020; 111: 154299.     CrossRef
  • Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review
    Siôn A. Parry, Leanne Hodson
    Advances in Therapy.2020; 37(4): 1381.     CrossRef
  • Diabetes and Metabolism Journal in 2020: Good to Great
    In-Kyung Jeong
    Diabetes & Metabolism Journal.2020; 44(1): 1.     CrossRef
  • Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
    Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee
    Diabetes & Metabolism Journal.2020; 44(3): 382.     CrossRef
  • Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies
    Chang-hua Zhang, Bu-gao Zhou, Jun-qing Sheng, Yang Chen, Ying-qian Cao, Chen Chen
    Pharmacological Research.2020; 159: 104984.     CrossRef
  • Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
    Kyung-Soo Kim, Byung-Wan Lee
    Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
  • Effects of sodium–glucose cotransporter 2 inhibitors on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
    Baodi Xing, Yuhang Zhao, Bingzi Dong, Yue Zhou, Wenshan Lv, Wenjuan Zhao
    Journal of Diabetes Investigation.2020; 11(5): 1238.     CrossRef
  • Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress
    Tamiris Ingrid Petito-da-Silva, Vanessa Souza-Mello, Sandra Barbosa-da-Silva
    Molecular and Cellular Endocrinology.2019; 498: 110539.     CrossRef
Complications
Higher Prevalence and Progression Rate of Chronic Kidney Disease in Elderly Patients with Type 2 Diabetes Mellitus
Kyung-Soo Kim, Seok Won Park, Yong-Wook Cho, Soo-Kyung Kim
Diabetes Metab J. 2018;42(3):224-232.   Published online May 31, 2018
DOI: https://doi.org/10.4093/dmj.2017.0065
  • 5,213 View
  • 73 Download
  • 30 Web of Science
  • 33 Crossref
AbstractAbstract PDFPubReader   
Background

To evaluate the prevalence of chronic kidney disease (CKD) and progression rate to CKD in elderly patients with type 2 diabetes mellitus (T2DM).

Methods

We investigated the medical records of 190 elderly patients (65 years or older) with T2DM from 2005 to 2011 in 6-month increments. Mean follow-up duration was 64.5 months. CKD was defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 and/or the presence of albuminuria.

Results

The mean age was 70.4 years and mean diabetes duration was 10.6 years. Among all the participants, 113 patients (59.5%) had CKD. The eGFR was significantly decreased between baseline (65.7±15.0 mL/min/1.73 m2) and the end of follow-up (52.7±17.5 mL/min/1.73 m2, P<0.001). At the end of follow-up, the prevalence of eGFR <60 mL/min/1.73 m2 had increased by 61.6% (at baseline, 44.2%). Furthermore, in patients with eGFR ≥60 mL/min/1.73 m2, the progression rate to more than CKD stage 3 was 39.6% at the end of follow-up; 30.2% of elderly diabetic patients had progressed to albuminuria from normoalbuminuria. Kaplan-Meier analysis showed that the time interval to worsening nephropathy was significantly shorter in elderly patients with diabetes duration ≥10 years than in those with diabetes duration <5 years (P=0.018).

Conclusion

CKD was commonly observed in older patients with T2DM, and the progression rate to CKD is also high. Consequently, it is important to identify and manage CKD as early as possible in elderly patients with T2DM, especially in those with diabetes duration ≥10 years.

Citations

Citations to this article as recorded by  
  • Assessing heatwave effects on disabled persons in South Korea
    Yeji Kang, Ingul Baek, Jongchul Park
    Scientific Reports.2024;[Epub]     CrossRef
  • Combination of Risks of BMI and Health-Related Lifestyles on Kidney Function in the Prediabetic Japanese Population: A Prospective Cohort Study
    Jou-Yin Chen, Shiqi Deng, Yukiko Wagatsuma
    International Journal of Environmental Research and Public Health.2023; 20(7): 5338.     CrossRef
  • Hormonal imbalance in patients with chronic renal failure in the pre-dialysis and dialysis periods (part1)
    I.P. Katerenchuk, S.T. Rustamyan, V.V. Talash, T.I. Yarmola
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2023; 19(1): 65.     CrossRef
  • The Beneficial Effect of Glycemic Control against Adverse Outcomes in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
    Dong-Hwa Lee
    Diabetes & Metabolism Journal.2023; 47(4): 484.     CrossRef
  • Association Between Continuous Glucose Monitoring-Derived Glycemia Risk Index and Albuminuria in Type 2 Diabetes
    Jee Hee Yoo, Ji Yoon Kim, Jae Hyeon Kim
    Diabetes Technology & Therapeutics.2023; 25(10): 726.     CrossRef
  • Global burden and influencing factors of chronic kidney disease due to type 2 diabetes in adults aged 20–59 years, 1990–2019
    Dandan Xie, Tianpeng Ma, Haoliang Cui, Jing Li, Aihua Zhang, Zhifeng Sheng, Yiqiang Xie
    Scientific Reports.2023;[Epub]     CrossRef
  • Effectiveness of Early Advanced Glycation End Product Accumulation Testing in the Diagnosis of Diabetes: A Health Risk Factor Analysis Using the Body Mass Index as a Moderator
    Yi Zhang, Tian Jiang, Chao Liu, Honglin Hu, Fang Dai, Li Xia, Qiu Zhang
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Causal association pathways between fetuin-A and kidney function: a mediation analysis
    Philip Etabee Bassey, Pawin Numthavaj, Sasivimol Rattanasiri, Piyamitr Sritara, Mark McEvoy, Boonsong Ongphiphadhanakul, Ammarin Thakkinstian
    Journal of International Medical Research.2022; 50(4): 030006052210828.     CrossRef
  • Advanced glycation end products and diabetes and other metabolic indicators
    Tian Jiang, Yi Zhang, Fang Dai, Chao Liu, Honglin Hu, Qiu Zhang
    Diabetology & Metabolic Syndrome.2022;[Epub]     CrossRef
  • Type 2 diabetes management in people aged over seventy-five years: targets and treatment strategies
    Theocharis Koufakis, Maria Grammatiki, Kalliopi Kotsa
    Maturitas.2021; 143: 118.     CrossRef
  • Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes Therapy.2021; 12(1): 171.     CrossRef
  • Chronic kidney disease progression in aged patients
    Murat Tuğcu, Dilek Barutçu Ataş
    International Urology and Nephrology.2021; 53(12): 2619.     CrossRef
  • Factors determining the clinical significance of dipeptidyl peptidase-4 inhibitors in the treatment of elderly patients with type 2 diabetes mellitus
    I. V. Glinkina, A. V. Balashova, A. S. Shyman, A. V. Oderij, S. A. Khan, G. E. Runova, T. B. Morgunova, V. V. Fadeev
    Meditsinskiy sovet = Medical Council.2021; (7): 56.     CrossRef
  • Effect of Oral carnosine supplementation on urinary TGF-β in diabetic nephropathy: a randomized controlled trial
    Narongrit Siriwattanasit, Bancha Satirapoj, Ouppatham Supasyndh
    BMC Nephrology.2021;[Epub]     CrossRef
  • Estimation of the prevalence of type 2 diabetes in combination with diabetic kidney disease and identification of the associated factors in patients attending primary hospitals in Anhui Province, China
    Li Xia, Lanlan Cheng, Tian Jiang, Chao Liu, Shiqi Zhang, Honglin Hu, Fang Dai, Qiu Zhang, Yunxia Lu
    Journal of International Medical Research.2021; 49(10): 030006052110512.     CrossRef
  • A STUDY TO EVALUATE THE EFFECT OF ANAEMIA IN TYPE-2 DIABETIC PATIENTS
    Radhika Maheshwari, Divya J., J. Sahayaraj, Muthukrishnan R.
    GLOBAL JOURNAL FOR RESEARCH ANALYSIS.2021; : 117.     CrossRef
  • Metformin treatment for patients with diabetes and chronic kidney disease: A Korean Diabetes Association and Korean Society of Nephrology consensus statement
    Kyu Yeon Hur, Mee Kyoung Kim, Seung Hyun Ko, Miyeun Han, Dong Won Lee, Hyuk-Sang Kwon
    Kidney Research and Clinical Practice.2020; 39(1): 32.     CrossRef
  • Metformin Treatment for Patients with Diabetes and Chronic Kidney Disease: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
    Kyu Yeon Hur, Mee Kyoung Kim, Seung Hyun Ko, Miyeun Han, Dong Won Lee, Hyuk-Sang Kwon
    Diabetes & Metabolism Journal.2020; 44(1): 3.     CrossRef
  • The prevalence of diabetic chronic kidney disease in adult Greek subjects with type 2 diabetes mellitus: A series from hospital-based diabetes clinics
    Ilias N. Migdalis, Nikolaos Papanas, Athanasios E. Raptis, Ioannis M. Ioannidis, Alexios E. Sotiropoulos, George D. Dimitriadis
    Diabetes Research and Clinical Practice.2020; 166: 108243.     CrossRef
  • Proteinuria Is Associated with Carotid Artery Atherosclerosis in Non-Albuminuric Type 2 Diabetes: A Cross-Sectional Study
    Jaehyun Bae, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
    Journal of Clinical Medicine.2020; 9(1): 136.     CrossRef
  • Renal status in elderly patients with type 2 diabetes
    Kazunaga Takamatsu
    Clinical and Experimental Nephrology.2020; 24(1): 53.     CrossRef
  • The fat mass, estimated glomerular filtration rate, and chronic inflammation in type 2 diabetic patients
    Tomáš Šálek, Alena Adamíková, Petr Ponížil
    Journal of Clinical Laboratory Analysis.2020;[Epub]     CrossRef
  • Insulin: Trigger and Target of Renal Functions
    Ana F. Pina, Diego O. Borges, Maria João Meneses, Patrícia Branco, Rita Birne, Antonio Vilasi, Maria Paula Macedo
    Frontiers in Cell and Developmental Biology.2020;[Epub]     CrossRef
  • Rate of kidney function decline and factors predicting progression of kidney disease in type 2 diabetes mellitus patients with reduced kidney function: A nationwide retrospective cohort study
    Wisit Kaewput, Charat Thongprayoon, Api Chewcharat, Ram Rangsin, Bancha Satirapoj, Chalermrat Kaewput, Picha Suwannahitatorn, Tarun Bathini, Michael A. Mao, Liam D. Cato, Andrew M. Harrison, Pradeep Vaitla, Wisit Cheungpasitporn
    Therapeutic Apheresis and Dialysis.2020; 24(6): 677.     CrossRef
  • Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes
    Jee Hee Yoo, Min Sun Choi, Jiyeon Ahn, Sung Woon Park, Yejin Kim, Kyu Yeon Hur, Sang-Man Jin, Gyuri Kim, Jae Hyeon Kim
    Diabetes Technology & Therapeutics.2020; 22(10): 768.     CrossRef
  • Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis
    Jaehyun Bae, Namki Hong, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Yong-ho Lee
    Journal of Clinical Medicine.2020; 9(3): 798.     CrossRef
  • Metformin Use and Risk of All-Cause Mortality and Cardiovascular Events in Patients With Chronic Kidney Disease—A Systematic Review and Meta-Analysis
    Yao Hu, Min Lei, Guibao Ke, Xin Huang, Xuan Peng, Lihui Zhong, Ping Fu
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • Treatment with Cinacalcet in Hemodialysis Patients with Severe Secondary Hyperparathyroidism, Influences Bone Mineral Metabolism and Anemia Parameters
    Maria Aktsiali, Theodora Papachrysanthou , Ioannis Griveas, Christos Andriopoulos, Panagiotis Sitaras, Ioannis K. Triantafyllopoulos , George I. Lambrou
    Current Drug Therapy.2020; 15(3): 249.     CrossRef
  • Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome
    Jung Beom Seo, Yeon-Kyung Choi, Hye-In Woo, Yun-A Jung, Sungwoo Lee, Seunghyeong Lee, Mihyang Park, In-Kyu Lee, Gwon-Soo Jung, Keun-Gyu Park
    Diabetes & Metabolism Journal.2019; 43(6): 830.     CrossRef
  • Glucometabolic characteristics and higher vascular complication risk in Korean patients with type 2 diabetes with non-albumin proteinuria
    Yongin Cho, Yong-ho Lee, Eun Seok Kang, Bong-soo Cha, Byung-wan Lee
    Journal of Diabetes and its Complications.2019; 33(8): 585.     CrossRef
  • Assessment of kidney function and associated risk factors among type 2 diabetic patients
    Moyad Jamal Shahwan, Nageeb Abdul galil Hassan, Rima Ahd Shaheen
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(4): 2661.     CrossRef
  • Influence of diabetes mellitus on patients with lumbar spinal stenosis: A nationwide population-based study
    Chang Kyu Lee, Sun Kyu Choi, Dong Ah Shin, Seong Yi, Yoon Ha, Keung Nyun Kim, Insoo Kim, Gregory W.J. Hawryluk
    PLOS ONE.2019; 14(3): e0213858.     CrossRef
  • Predictores de progresión de enfermedad renal en el paciente anciano
    Manuel Heras Benito, Mª José Fernández Reyes Luis
    Enfermería Nefrológica.2019; 22(1): 19.     CrossRef
Clinical Care/Education
Self-Monitoring of Blood Glucose in Patients with Insulin-Treated Type 2 Diabetes Mellitus
Kyung-Soo Kim
Diabetes Metab J. 2018;42(1):26-27.   Published online February 23, 2018
DOI: https://doi.org/10.4093/dmj.2018.42.1.26
  • 3,337 View
  • 50 Download
  • 2 Web of Science
  • 3 Crossref
PDFPubReader   

Citations

Citations to this article as recorded by  
  • Association between frequency of self-monitoring of blood glucose and glycemic control in patients with type 2 diabetes
    Xiaoyan Sun, Xianghai Zhou, Shaobo Li, Linong Ji
    Diabetes Research and Clinical Practice.2024; 209: 111027.     CrossRef
  • Epidemiological profile and diabetes control of Type 1 Diabetes Mellitus patients in Karbala Governorate, Iraq
    Abdul Razzaq Oleiwi Jasim, Noor Abdul Razzaq, Ali Thoulfikar A. Imeer, Rahem Mahdi Rahem, Abdul Amir H. Kadhum, Ahmed A. Al-Amiery
    F1000Research.2023; 12: 409.     CrossRef
  • Evaluating the impact of self‐monitoring of blood glucose frequencies on glucose control in patients with type 2 diabetes who do not use insulin: A systematic review and meta‐analysis
    Yingqi Xu, David Hsien Yung Tan, Joyce Yu‐Chia Lee
    International Journal of Clinical Practice.2019;[Epub]     CrossRef
Letter: The Association of Serum Cystatin C with Glycosylated Hemoglobin in Korean Adults (Diabetes Metab J 2016;40:62-9)
Kyung-Soo Kim
Diabetes Metab J. 2016;40(2):171-172.   Published online April 25, 2016
DOI: https://doi.org/10.4093/dmj.2016.40.2.171
  • 2,564 View
  • 30 Download
PDFPubReader   
The Clinical Characteristics of the Newly Diagnosed Early Onset (< 40 Years Old) Diabetes in Outpatients' Clinic
Kyung-Soo Kim, Hyun-Ju Oh, Ji-Woon Kim, Yeo-Kyung Lee, Soo-Kyung Kim, Seok-Won Park, Yoo-Lee Kim, Won-Keun Park, Yong-Wook Cho
Korean Diabetes J. 2010;34(2):119-125.   Published online April 30, 2010
DOI: https://doi.org/10.4093/kdj.2010.34.2.119
  • 4,035 View
  • 42 Download
  • 16 Crossref
AbstractAbstract PDFPubReader   
Background

The prevalence of type 2 diabetes in young adults and adolescents has increased in the last decade according to the increasing obese population. The aim of this study was to examine the clinical characteristics of patients diagnosed with diabetes mellitus before the age of 40 years as compared with patients diagnosed at older ages.

Methods

This was a cross-sectional, retrospective study using data from 350 diabetic patients who were diagnosed with diabetes in an outpatient setting between January 2005 and December 2007. Patients were diagnosed according to the criteria set forth by the American Diabetes Association. We examined the clinical characteristics and laboratory data of the patients through review of medical records and compared the early-onset diabetic patients (< 40 years old) and the usual-onset diabetic patients (≥ 40 years old).

Results

The frequency of early-onset diabetes and usual-onset diabetes were 31.1% (n=109) and 68.9% (n=241), respectively. The early-onset diabetic patients more often had a positive family history of diabetes; higher HbA1c, fasting glucose, and postprandial glucose levels; experienced typical symptoms more frequently; had microalbuminuria more frequently; and required insulin therapy as initial treatment more frequently as compared to usual-onset diabetic patients, and these differences were significant. Conversely, hypertension was significantly more common in the usual-onset diabetic patients.

Conclusion

It could be concluded that we should control early onset diabetes more strictly to prevent its complication because early onset diabetic patients represented more severe hyperglycemia and had more prevalent microalbuminuria.

Citations

Citations to this article as recorded by  
  • Clinical features of early-onset type 2 diabetes and its association with triglyceride glucose-body mass index: a cross-sectional study
    Yanjuan Jiang, Xiaoyang Lai
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Clinical characteristics of patients with early-onset diabetes mellitus: a single-center retrospective study
    Wenjing Dong, Saichun Zhang, Shiju Yan, Zhizhuang Zhao, Zengqiang Zhang, Weijun Gu
    BMC Endocrine Disorders.2023;[Epub]     CrossRef
  • Factors Associated with Chronic Disease and Health Care Utilization Among Young Adults in South Korea
    Jongho Park, Yeaeun Kim
    Population Health Management.2022; 25(3): 407.     CrossRef
  • Therapeutic potential of dopamine agonists in the treatment of type 2 diabetes mellitus
    Md. Tanvir Kabir, Jannatul Ferdous Mitu, Raushanara Akter, Muhammad Furqan Akhtar, Ammara Saleem, Ahmed Al-Harrasi, Saurabh Bhatia, Md. Sohanur Rahman, Fouad Damiri, Mohammed Berrada, Md. Habibur Rahman
    Environmental Science and Pollution Research.2022; 29(31): 46385.     CrossRef
  • Characteristics of Glycemic Control and Long-Term Complications in Patients with Young-Onset Type 2 Diabetes
    Han-sang Baek, Ji-Yeon Park, Jin Yu, Joonyub Lee, Yeoree Yang, Jeonghoon Ha, Seung Hwan Lee, Jae Hyoung Cho, Dong-Jun Lim, Hun-Sung Kim
    Endocrinology and Metabolism.2022; 37(4): 641.     CrossRef
  • The Difference in Risk Factors Between Adults With Early-Onset (<40 Years Old) Versus Late-Onset (≥40 Years Old) Type 2 Diabetes in a University Hospital From January 2015-December 2017
    Marilyn Katrina C Caro, Elaine C Cunanan
    Journal of Medicine, University of Santo Tomas.2022; 6(2): 1009.     CrossRef
  • Comparison of clinical features, complication profile, and achievement of guideline targets in early- and late-onset type 2 diabetes patients from North India
    Hamid Ashraf, Ahmad Faraz, Jamal Ahmad
    International Journal of Diabetes in Developing Countries.2021; 41(3): 396.     CrossRef
  • Questionnaire-based Survey of Demographic and Clinical Characteristics, Health Behaviors, and Mental Health of Young Korean Adults with Early-Onset Diabetes
    Ji In Park, Hyunjeong Baek, Sang-Wook Kim, Ji Yun Jeong, Kee-Ho Song, Ji Hee Yu, Il Sung Nam-Goong, Eun-Hee Cho
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • Association among Lifestyle Factors, Obesity, C-peptide Secretion, Metabolic Syndrome, and Cardiovascular Risk in Adults with Newly Diagnosed Type 2 Diabetes Mellitus: A Case Study
    Sun-Young Kwon, Hye-Ja Park
    Journal of Health Informatics and Statistics.2019; 44(2): 125.     CrossRef
  • Type 2 diabetes in adolescents and young adults
    Nadia Lascar, James Brown, Helen Pattison, Anthony H Barnett, Clifford J Bailey, Srikanth Bellary
    The Lancet Diabetes & Endocrinology.2018; 6(1): 69.     CrossRef
  • The relationship between age of onset and risk factors including family history and life style in Korean population with type 2 diabetes mellitus
    Jin-Won Noh, Jin Hee Jung, Jeong Eun Park, Jung Hwa Lee, Kang Hee Sim, Jumin Park, Min Hee Kim, Ki-Bong Yoo
    Journal of Physical Therapy Science.2018; 30(2): 201.     CrossRef
  • Early-onset diabetes: an epidemic in China
    Jiemin Pan, Weiping Jia
    Frontiers of Medicine.2018; 12(6): 624.     CrossRef
  • Distinct Predictors and Comorbidities in Early Onset Type 2 Diabetes Mellitus Among Asian Indians
    Gadadharan Vijayakumar, Ganapathy K. Sreehari, Aswathi Vijayakumar, Abdul Jaleel
    Metabolic Syndrome and Related Disorders.2017; 15(9): 458.     CrossRef
  • A Predictive Model of Health Outcomes for Young People with Type 2 Diabetes
    Sun Young Jung, Sook Ja Lee, Sun Hee Kim, Kyung Mi Jung
    Asian Nursing Research.2015; 9(1): 73.     CrossRef
  • An assessment of the impact of type 2 diabetes on the quality of life based on age at diabetes diagnosis
    Jin Ook Chung, Dong Hyeok Cho, Dong Jin Chung, Min Young Chung
    Acta Diabetologica.2014; 51(6): 1065.     CrossRef
  • Characteristics, complications and management of a large multiethnic cohort of younger adults with type 2 diabetes
    Katrien Benhalima, Soon H. Song, Emma G. Wilmot, Kamlesh Khunti, Laura J. Gray, Ian Lawrence, Melanie Davies
    Primary Care Diabetes.2011; 5(4): 245.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal